Home › Compare › IMBIL vs ABBV
IMBIL yields 216.73% · ABBV yields 3.06%● Live data
📍 IMBIL pulled ahead of the other in Year 1
Combined, IMBIL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IMBIL + ABBV for your $10,000?
iMedia Brands, Inc. operates as a multiplatform interactive video and digital commerce company in the United States. It operates through two segments, ShopHQ and Emerging. The company markets, sells, and distributes products to consumers through television, website, mobile, social media, and over-the-top platforms in various merchandise categories, such as jewelry and watches, which include silver, gold, and gemstones to simulated diamonds; home and consumer electronics comprising home décor, cookware, kitchen electrics, tabletop accessories, and home furnishings; beauty and wellness products, such as skincare, cosmetics, hair care, and bath and body products; and fashion and accessories, including apparel, outerwear, intimates, handbags, accessories, and footwear. It has access to approximately 80 million homes primarily on cable and satellite systems, as well as offers its products through online at OurGalleria.com and TheCloseout.com. The company was formerly known as EVINE Live Inc. and changed its name to iMedia Brands, Inc. in July 2019. iMedia Brands, Inc. was incorporated in 1990 and is headquartered in Eden Prairie, Minnesota.
Full IMBIL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.